AR and prostate carcinoma: SCNC is rare in primary PCa [4], whereas about 10–17% of patients with metastatic androgen deprivation-resistant prostate cancer (ARPC) have been reported to develop treatment-related SCNC (t-SCNC) after receiving second-generation androgen receptor pathway inhibitors (ARPIs) [5].